Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAG | P20916 | 10/20 | 0.69 |
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.66 |
| ▸ | SELP | P16109 | 2/20 | 0.65 |
| ▸ | SELL | P14151 | 1/20 | 0.65 |
| ▸ | SELE | P16581 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29581047 | 1.00 | MAG (0.69) | MAGSIGLEC7SELPSELLSELE | |
| SCHEMBL29392992 | 1.00 | MAG (0.69) | MAGSIGLEC7SELPSELLSELE | |
| SCHEMBL29460415 | 1.00 | MAG (0.69) | MAGSIGLEC7SELPSELLSELE | |
| SCHEMBL26491833 | 1.00 | MAG (0.69) | MAGSIGLEC7SELPSELLSELE | |
| SCHEMBL30122574 | 0.96 | SIGLEC7 (0.72) | MAGSIGLEC7SELPSELLSELE | |
| SCHEMBL29532796 | 0.96 | SIGLEC7 (0.72) | MAGSIGLEC7SELPSELLSELE | |
| SCHEMBL29532570 | 0.96 | SIGLEC7 (0.72) | MAGSIGLEC7SELPSELLSELE | |
| SCHEMBL12847918 | 0.96 | SIGLEC7 (0.69) | MAGSIGLEC7SELPSELLSELE | |
| SCHEMBL29532935 | 0.96 | SIGLEC7 (0.69) | MAGSIGLEC7SELPSELLSELE | |
| SCHEMBL29432531 | 0.96 | SIGLEC7 (0.69) | MAGSIGLEC7SELPSELLSELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240301178-A1 | POLYSACCHARIDE COMPLEX | ACARYON GMBH (DE) | 2024-09-12 | — | — | US | claimed |
| US-20260109747-A1 | Conjugate Comprising an IL-2 Moiety | ASCENDIS PHARMA ONCOLOGY DIV A/S (DK) | 2026-04-23 | — | — | US | disclosed |
| US-12428461-B2 | Treating cancer with a conjugate comprising an IL-2 moiety | Ascendis Pharma Oncology Division A/S (DK) | 2025-09-30 | — | — | US | disclosed |
| US-20250001009-A1 | THERAPY FOR PROGRAMMED CELL DEATH IN A SUBJECT TRANSPLANTED WITH A DONOR LIVER CARRYING THE PNPLA3 RS738409:G VARIANT | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-01-02 | — | — | US | disclosed |
| US-20240355424-A1 | CLINICAL DIAGNOSTICS USING GLYCANS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-10-24 | — | — | US | disclosed |
| US-20240301178-A1 | POLYSACCHARIDE COMPLEX | ACARYON GMBH (DE) | 2024-09-12 | — | — | US | disclosed |
| EP-4370664-A1 | LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES | Inbiose N.V. (BE) | 2024-05-22 | — | — | EP | disclosed |
| US-11879001-B2 | Conjugate comprising an IL-2 moiety | Ascendis Pharma Oncology Division A/S (DK) | 2024-01-23 | — | — | US | disclosed |
| US-20230340055-A1 | GLYCOSYLATED IL-2 PROTEINS AND USES THEREOF | Ascendis Pharma Oncology Division A/S (DK) | 2023-10-26 | — | — | US | disclosed |
| US-20230201355-A1 | IL-2 SEQUENCES AND USES THEREOF | Ascendis Pharma Oncology Division A/S (DK) | 2023-06-29 | — | — | US | disclosed |
| US-20230174605-A1 | IL-2 SEQUENCES AND USES THEREOF | Ascendis Pharma Oncology Division A/S (DK) | 2023-06-08 | — | — | US | disclosed |
| WO-2023285650-A1 | LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES | INBIOSE N.V. (BE) | 2023-01-19 | — | — | WO | disclosed |
| US-20220380785-A1 | COMPOSITIONS AND METHODS FOR SIALYLATED MUCIN-TYPE O-GLYCOSYLATION OF THERAPEUTIC PROTEINS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340055-A1 | GLYCOSYLATED IL-2 PROTEINS AND USES THEREOF | IL2, IL1A, ILF2 | MAG 1148/4885SIGLEC7 372/4885SELP 1976/4885 |
| US-20230201355-A1 | IL-2 SEQUENCES AND USES THEREOF | IL2, IL2RA, IL4I1 | MAG 3384/4885SIGLEC7 1156/4885SELP 2634/4885 |
| US-20260109747-A1 | Conjugate Comprising an IL-2 Moiety | IL2, IL2RA, ILF2 | MAG 3051/4885SIGLEC7 544/4885SELP 1018/4885 |
| US-12428461-B2 | Treating cancer with a conjugate comprising an IL-2 moiety | IL2, IL2RA, ILF2 | MAG 2446/4885SIGLEC7 486/4885SELP 2082/4885 |
| US-11879001-B2 | Conjugate comprising an IL-2 moiety | IL2, IL2RA, IL4I1 | MAG 2616/4885SIGLEC7 599/4885SELP 2355/4885 |
| US-20240301178-A1 | POLYSACCHARIDE COMPLEX | SGMS1, UGCG, SGMS2 | MAG 181/4885SIGLEC7 64/4885SELP 241/4885 |
| US-20230174605-A1 | IL-2 SEQUENCES AND USES THEREOF | IL2, IL2RA, IL4I1 | MAG 3384/4885SIGLEC7 1156/4885SELP 2634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.